ReviewThe Journal of clinical investigation2017
Discovery, characterization, and clinical development of the glucagon-like peptides.
Review in The Journal of clinical investigation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 227 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
227 citing papers in PubMed, 2 syntheses or guidelines pooled it, 387 citations in OpenAlex.
- A Systematic Review to Reassess the Formula for Early Life Growth.Advances in nutrition (Bethesda, Md.) · 2026Pooled it
- Glucagon-like Peptide-1 receptor agonists for obstructive sleep apnea in patients with obesity and type 2 diabetes mellitus: a systematic review and meta-analysis.Journal of translational medicine · 2025Pooled it
- Oral nonpeptide GLP-1 receptor agonist VCT220 for obesity treatment: a randomized, double-blind, phase II trial.Signal transduction and targeted therapy · 2026Trial
- Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial.Diabetologia · 2026Trial
- Efsubaglutide alfa added to metformin improves glycaemia with β-cell functional responses in type 2 diabetes: a randomised, double-blind, placebo-controlled, two-stage adaptive phase 2b/3 trial (SUPER 2).Nature communications · 2026Trial
- Association Between Circulating Gremlin 2 and β-Cell Function Among Participants With Prediabetes and Type 2 Diabetes.Journal of diabetes · 2025Trial
- Non-clinical and first-in-human characterization of ECC5004/AZD5004, a novel once-daily, oral small-molecule GLP-1 receptor agonist.Diabetes, obesity & metabolism · 2025Trial
- Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial.JAMA network open · 2023Trial
- A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese adults with type 2 diabetes mellitus.Diabetes, obesity & metabolism · 2023Trial
- Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes.Cell reports. Medicine · 2021Trial
- Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial.Nature medicine · 2021Trial
- Evaluation of the substrate profile of microbial-host-isozyme reveals the role of BvDPP4 in inflammatory bowel disease.Science China. Life sciences · 2026Article
- Efsubaglutide Alfa: A Comprehensive Pharmacological Review.Clinical pharmacokinetics · 2026Review
- Lipid sensing and brain hormone receptors in food intake and glucose regulation.Nature reviews. Endocrinology · 2026Review
- Foods as Modulators of GLP-1 Secretion.Nutrients · 2026Review
- Preoperative fasting status and retained gastric contents in patients undergoing endoscopy who are using glucagon-like peptide type 1 receptor agonists: a multicentre retrospective study.Canadian journal of anaesthesia = Journal canadien d'anesthesie · 2026Article
- Article
- Impact of GLP-1 and GLP-1/GIP receptor agonists before, during, and after pregnancy: a narrative review.Diabetology & metabolic syndrome · 2026Review
- ADHD and cardiometabolic risk profile in adults with type 2 diabetes: a longitudinal register-based study.BMJ open · 2026Article
- DNA-based delivery of incretin receptor agonists using MYO Technology leads to durable weight loss in a diet-induced obesity model.Molecular therapy. Nucleic acids · 2026Article
167 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discovery, characterization, and clinical development of glucagon-like-peptide-1 (GLP-1) spans more than 30 years and includes contributions from multiple investigators, science recognized by the 2017 Harrington Award Prize for Innovation in Medicine. Herein, we provide perspectives on the historical events and key experimental findings establishing the biology of GLP-1 as an insulin-stimulating glucoregulatory hormone. Important attributes of GLP-1 action and enteroendocrine science are reviewed, with emphasis on mechanistic advances and clinical proof-of-concept studies. The discovery that GLP-2 promotes mucosal growth in the intestine is described, and key findings from both preclinical studies and the GLP-2 clinical development program for short bowel syndrome (SBS) are reviewed. Finally, we summarize recent progress in GLP biology, highlighting emerging concepts and scientific insights with translational relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.